๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC
Phase 2
355
Beijing, Guangzhou, Shanghai, Chengdu
2021-08-12
Recruiting
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
NCT04891198Solid Tumor
3D Medicines (Sichuan) Co., Ltd.
Phase 2
126
Beijing
2021-08-06
Recruiting
Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline
NCT05014893Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy
National Research Center for Rehabilitation Technical Aids
Not applicable
100
Beijing
2021-08-06
By invitation
IT Matters: The Erectile Restoration Registry
NCT04200937Erectile Dysfunction
Boston Scientific Corporation
Observational
450
Beijing, Shanghai
2021-08-05
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Haerbin, Linyi, Beijing, Shanghai
2021-08-04
Recruiting
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
Chinese PLA General Hospital
Phase 1/2
90
Beijing
2021-08-04
Recruiting
Closed-loop Functional Spinal Cord Stimulation in Patients With Spinal Cord Injury
NCT04969042Spinal Cord Injuries
Luming Li
Phase 1
10
Beijing
2021-08-01
By invitation
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
NCT06101940Myotonic Dystrophy 1
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT04907370Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
By invitation
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
NCT06759857Non Small Cell Lung Cancer
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 3
350
Beijing
2021-08-01
By invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459Non-small Cell Lung Carcinoma
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
Guangzhou, Wuhan, Beijing, Shanghai
2021-07-28
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Phase 3
208
Beijing, Tianjin
2021-07-27
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Active, closed
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
NCT05009329NSCLC, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
By invitation
The GUARDIAN Trial - Induction Agent Sub-Study
NCT04934683Major Surgery
The University of Texas Health Science Center, Houston
Phase 4
6,254
Shanghai, Beijing, Sichuan
2021-07-25
Recruiting
The GUARDIAN Trial
NCT04884802Blood Pressure
The University of Texas Health Science Center, Houston
Not applicable
6,254
Beijing, Chengdu, Hong Kong, Shanghai, Xuzhou
2021-07-25
By invitation
The GUARDIAN Trial - Vasopressor Sub-Study
NCT04934748Blood Pressure
The University of Texas Health Science Center, Houston
Phase 4
6,254
Beijing, Shanghai, Sichuan
2021-07-25
Active, closed
Newly Diagnosed Glioblastoma
NCT04959500Glioblastoma
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
NCT05712902Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
Evolut PRO China Clinical Study
NCT04982588Severe, Symptomatic Aortic Stenosis
Medtronic Cardiovascular
Not applicable
52
Beijing, Chengdu, Hangzhou
2021-07-17
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
Biogen
Phase 3
562
Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan
2021-07-16
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFฮฑ Inhibitor Treatment
NCT04908189Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Active, closed
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
NCT04898634Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
216
Beijing, Chongqing, Guangzhou, Wenzhou
2021-07-13
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Recruiting
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
200
Beijing, Guangzhou
2021-07-06
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
EyeConic: Qualification for Cone-Optogenetics
NCT05294978Retinal Dystrophies
Institute of Molecular and Clinical Ophthalmology Basel
Observational
1,000
Beijing
2021-07-01
Recruiting
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
NCT05283993Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
Peking University First Hospital
Observational
2,000
Beijing
2021-07-01
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye
NCT06696625Dry Eye Disease
Beijing Tongren Hospital
Not applicable
256
Beijing
2021-07-01
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease
NCT04673643Dry Eye Disease
Beijing Tongren Hospital
Phase 2
128
Beijing
2021-07-01
Not yet open
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
NCT04956601Endometrial Cancer, Pathology, Radiotherapy
Peking University Third Hospital
Not applicable
480
Beijing
2021-07
Not yet open
Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
NCT04976478Cervical Squamous Cell Carcinoma
Peking University Third Hospital
Observational
125
Beijing
2021-07
Active, closed
Phase ll Study of HEC585 in Patients With IPF
NCT05060822Idiopathic Pulmonary Fibrosis
Sunshine Lake Pharma Co., Ltd.
Phase 2
270
Beijing
2021-06-30
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994Gastric Cancer
Idience Co., Ltd.
Phase 1/2
87
Beijing, Guangzhou, Shanghai
2021-06-28
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
By invitation
Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
NCT04961450Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Motor Neuron Disease
Peking University Third Hospital
Observational
2,500
Beijing
2021-06-24
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05171816Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Recruiting
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
NCT04912843Leber's Hereditary Optic Neuropathy (LHON)
Wuhan Neurophth Biotechnology Limited Company
Phase 2/3
102
Beijing
2021-06-18
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Recruiting
Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis
NCT07046988Tinea Capitis
Shandong University
Observational
60
Beijing
2021-06-15
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
NCT04765592Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Active, closed
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
NCT05058040Alzheimer Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
2,500
Hefei, Beijing, Chongqing, Xianmencun, Dongguan, Guangzhou, Shenzhen, Zhuhai
2021-06-02
Recruiting
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
NCT04834024Follicular Lymphoma and Marginal Zone Lymphoma
Beijing Mabworks Biotech Co., Ltd.
Phase 3
168
Beijing
2021-06-02
Recruiting
Comparison of MBR + Suture Tape and MBR for CLAI : A Prospective Cohort Study
NCT06897293Ankle Sprain, Hypermobility, Joint
Peking University Third Hospital
Observational
86
Beijing
2021-06-01
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Recruiting
Pneumoconiosis and Dust Exposure China Cohort
NCT07077382Pneumoconiosis
China-Japan Friendship Hospital
Observational
2,000
Beijing
2021-05-28
Active, closed
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Active, closed
An Observational Study of Long-term Peritoneal Dialysis Patients Who Eventually Develop Ultrafiltration Failure (LUFF)
NCT05721703Ultrafiltration Failure
Chinese PLA General Hospital
Observational
150
Beijing
2021-05-21
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
NCT03944239Retinitis Pigmentosa
Qi Zhou
Phase 1
25
Beijing
2021-05-19
Active, closed
Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix
NCT06771596Uterine Cervical Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
43
Beijing
2021-05-12
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
Hoffmann-La Roche
Phase 3
761
Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2021-05-03
Recruiting
Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis
NCT04815668Seasonal Allergic Rhinitis
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
120
Beijing
2021-05-01
Recruiting
XuanwuH Acute Ischemic Stroke Registry
NCT05208203Acute Ischemic Stroke
Xuanwu Hospital, Beijing
Observational
500
Beijing
2021-05-01
Recruiting
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
NCT04857164Head and Neck Squamous Cell Carcinoma
Yuankai Shi
Phase 2
150
Beijing
2021-04-30
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Recruiting
Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy
NCT04852406Antithrombotic Therapy, Perioperative Care, Perioperative Outcomes
Peking University First Hospital
Not applicable
526
Beijing
2021-04-21
Active, closed
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04649489Venous Thrombosis
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Recruiting
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
NCT04834544Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Peking University Third Hospital
Phase 2
75
Beijing
2021-04-19
Active, closed
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
Phase 2
206
Beijing, Shanghai
2021-04-19
Active, closed
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
NCT04697940Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells
Han weidong
Phase 1/2
33
Beijing
2021-04-15
By invitation
MInithoraCotomy vs Sternotomy for Multivessel Coronary Artery Bypass Grafting: A Partially Randomized Patient Preference Trial Assessing Quality of Life and Patency Outcomes
NCT04795193Coronary Artery Bypass, Off-Pump, Minimally Invasive Cardiac Surgery
Peking University Third Hospital
Not applicable
248
Beijing
2021-04-15
Active, closed
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)
Takeda
Phase 3
77
Beijing, Wuhan, Suzhou, Tianjin
2021-04-14
Recruiting
Different Immunosuppressive Treatment in iMN
NCT04745728Idiopathic Membranous Nephropathy
Peking Union Medical College Hospital
Phase 3
200
Beijing
2021-04-14
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Recurrent Glioma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,854
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Active, closed
Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis
NCT04971980Rheumatoid Arthritis
Beijing Baylx Biotech Co., Ltd.
Phase 1/2
9
Beijing
2021-04-12
Recruiting
HANGZHOU Solution in Bicuspid AS Undergoing TAVR
NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
508
Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2021-04-12
Recruiting
Three Cancellous Screws Versus Four Cancellous Screws for Femoral Neck Fixation
NCT04869332Femoral Neck Fractures, Internal Fixation
Peking University Third Hospital
Not applicable
290
Beijing
2021-04-08
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Recruiting
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
NCT04836156HER2-negative Early Breast Cancer
Peking University People's Hospital
Phase 1/2
46
Beijing
2021-04-02
Recruiting
Association Between Stroke and Adrenal Incidentalomas
NCT05237817Stroke, Adrenal Incidentaloma
Xuanwu Hospital, Beijing
Observational
2
Beijing
2021-04-01
Recruiting
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
NCT06194617Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
Peking Union Medical College Hospital
Observational
300
Beijing
2021-04-01
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Recruiting
Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
NCT05901818Parkinson's Disease
Xuanwu Hospital, Beijing
Phase 1
6
Beijing
2021-04-01
Active, closed
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
NCT05434312Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Beijing
2021-03-29
Recruiting
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
NCT04750122HER2-positive Early Breast Cancer
Peking University People's Hospital
Phase 1/2
46
Beijing
2021-03-28
Active, closed
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT04954001Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2
160
Beijing, Guangzhou, Hangzhou, Shanghai, Shijiazhuang, Wuhan
2021-03-26
Recruiting
Mi-thosยฎ Transcatheter Mitral Valve Replacement Study
NCT04195984Mitral Valve Regurgitation
Shanghai NewMed Medical Co., Ltd.
Not applicable
122
Beijing, Shanghai, Xiโ€™an
2021-03-25
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Active, closed
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870Myelofibrosis
Karyopharm Therapeutics Inc
Phase 2
112
Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou
2021-03-17
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Recruiting
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
NCT06189391Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Active, closed
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Not yet open
Precision Medicine Study on Cardiovascular Disease (PRECISE)
NCT04434911Cardiovascular Diseases
China National Center for Cardiovascular Diseases
Observational
20,000
Beijing
2021-03-10
Recruiting
PM8002 in the Treatment of Patients With Advanced Solid Tumors
NCT05918445Malignant Neoplasm
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
238
Beijing, Xicheng District, Lanzhou, Guangzhou, Haikou, Zhengzhou, Changsha, Xuzhou
2021-03-09
Rows per page Showing 4901–5000 of 5484
Previous 48 49 50 51 52 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=50

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.